Sigma Healthcare (ASX:SIG) reported a rise in financial performance for the half-year ended Dec. 31, 2025, driven by the integration of Chemist Warehouse and robust retail sales.
The merged group recorded a 14.9% increase in revenue to $5.5 billion compared to the prior corresponding period.
Profitability metrics also saw significant double-digit growth, with normalised EBIT rising 18.7% to $582.9 million and normalised NPAT growing 19.2% to $392.0 million.
A primary driver of this growth was the Australian CW branded store network, which saw sales climb 17.2% to reach $5.1 billion.
Like-for-like sales within the domestic network grew by 15.0%, a result the company attributes to its pharmacy model, strong customer engagement, and a strategic shift toward distributing online orders directly from stores.
Additionally, the group benefited from a structural uplift in the sale of GLP-1 class medicines.
International expansion also accelerated during the period, with retail network sales jumping 24.5% and LFL sales up 11.1%.
On the balance sheet, Sigma demonstrated improved financial health by reducing net debt by $117.1 million to $635.1 million, bringing its leverage down to a conservative 0.6x normalised EBITDA.
The CEO noted that the results reinforce the strength of the integrated healthcare business.